Department of Epidemiology, Gillings School of Global Public Health, The University of North Carolina at Chapel Hill.
Department of Epidemiology, Brown University, Providence, Rhode Island.
JAMA Psychiatry. 2018 Apr 1;75(4):379-385. doi: 10.1001/jamapsychiatry.2017.4726.
Depression commonly affects adults with HIV and complicates the management of HIV. Depression among individuals with HIV tends to be chronic and cyclical, but the association of this chronicity with HIV outcomes (and the related potential for screening and intervention to shorten depressive episodes) has received little attention.
To examine the association between increased chronicity of depression and multiple HIV care continuum indicators (HIV appointment attendance, treatment failure, and mortality).
DESIGN, SETTING, AND PARTICIPANTS: The study comprised an observational clinical cohort of 5927 patients with 2 or more assessments of depressive severity who were receiving HIV primary care at 6 geographically dispersed US academic medical centers from September 22, 2005, to August 6, 2015.
Missing a scheduled HIV primary care visit, detectable HIV RNA viral load (≥75 copies/mL), and all-cause mortality. Consecutive depressive severity measures were converted into a time-updated measure: percentage of days with depression (PDD), following established methods for determining depression-free days.
During 10 767 person-years of follow-up, the 5927 participants (5000 men, 926 women, and 1 intersex individual; median age, 44 years [range, 35-50 years]) had a median PDD of 14% (interquartile range, 0%-48%). During follow-up, 10 361 of 55 040 scheduled visits (18.8%) were missed, 6191 of 28 455 viral loads (21.8%) were detectable, and the mortality rate was 1.5 deaths per 100 person-years. Percentage of days with depression showed a dose-response relationship with each outcome. Each 25% increase in PDD led to an 8% increase in the risk of missing a scheduled appointment (risk ratio, 1.08; 95% CI, 1.05-1.11), a 5% increase in the risk of a detectable viral load (risk ratio, 1.05; 95% CI, 1.01-1.09), and a 19% increase in the mortality hazard (hazard ratio, 1.19; 95% CI, 1.05-1.36). These estimates imply that, compared with patients who spent no follow-up time with depression (PDD, 0%), those who spent the entire follow-up time with depression (PDD, 100%) faced a 37% increased risk of missing appointments (risk ratio, 1.37; 95% CI, 1.22-1.53), a 23% increased risk of a detectable viral load (risk ratio, 1.23; 95% CI, 1.06-1.43), and a doubled mortality rate (hazard ratio, 2.02; 95% CI, 1.20-3.42).
Greater chronicity of depression increased the likelihood of failure at multiple points along the HIV care continuum. Even modest increases in the proportion of time spent with depression led to clinically meaningful increases in negative outcomes. Clinic-level trials of protocols to promptly identify and appropriately treat depression among adults living with HIV should be conducted to understand the effect of such protocols on shortening the course and preventing the recurrence of depressive illness and improving clinical outcomes.
抑郁症常影响艾滋病毒感染者,并使艾滋病毒的管理复杂化。艾滋病毒感染者的抑郁症往往具有慢性和周期性,但这种慢性与艾滋病毒结果的关联(以及相关的筛查和干预以缩短抑郁发作的潜在可能性)尚未得到关注。
研究抑郁慢性程度增加与多项艾滋病毒护理连续体指标(艾滋病毒预约就诊、治疗失败和死亡率)之间的关联。
设计、地点和参与者:本研究包括在 6 个美国学术医疗中心接受艾滋病毒初级保健的 5927 名患者的观察性临床队列,这些患者在 2005 年 9 月 22 日至 2015 年 8 月 6 日期间接受了 2 次或更多次抑郁严重程度评估。
错过预定的艾滋病毒初级保健就诊、可检测到的 HIV RNA 病毒载量(≥75 拷贝/ml)和全因死亡率。连续的抑郁严重程度测量值被转换为时间更新的测量值:抑郁天数百分比(PDD),遵循确定无抑郁天数的既定方法。
在 10767 人年的随访期间,5927 名参与者(5000 名男性,926 名女性和 1 名双性人;中位数年龄为 44 岁[范围为 35-50 岁])的 PDD中位数为 14%(四分位距,0%-48%)。在随访期间,55040 次预定就诊中有 10361 次(18.8%)被错过,28455 次病毒载量中有 6191 次(21.8%)可检测到,死亡率为每 100 人年 1.5 例死亡。PDD 与每种结局均呈剂量反应关系。PDD 每增加 25%,预约就诊错过的风险增加 8%(风险比,1.08;95%CI,1.05-1.11),可检测到的病毒载量的风险增加 5%(风险比,1.05;95%CI,1.01-1.09),死亡率危险增加 19%(风险比,1.19;95%CI,1.05-1.36)。这些估计表明,与没有任何随访时间患有抑郁症(PDD,0%)的患者相比,整个随访时间患有抑郁症(PDD,100%)的患者错过就诊的风险增加 37%(风险比,1.37;95%CI,1.22-1.53),可检测到的病毒载量的风险增加 23%(风险比,1.23;95%CI,1.06-1.43),死亡率增加一倍(风险比,2.02;95%CI,1.20-3.42)。
抑郁的慢性程度增加使艾滋病毒护理连续体的多个点发生失败的可能性增加。即使抑郁时间比例略有增加,也会导致临床有意义的不良后果增加。应开展针对艾滋病毒感染者的协议进行临床试验,以了解这些协议对缩短抑郁病程和预防抑郁复发以及改善临床结局的影响。